Clinical and economic evaluation of a surveillance protocol to manage hepatitis B virus (HBV) reactivation among lymphoma patients with resolved HBV infection receiving rituximab
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy2021Vol. 41(4), pp. 332–341
Citations Over Time
Chia Jie Tan, Rajneesh Kumar, Narendran Koomanan, Wei Sheng Loo, Mohamad Farid, Miriam Tao, Nagavalli Somasundaram, Eileen Poon, Jason Yongsheng Chan, Valerie Shiwen Yang, Esther Wei Yin Chang, Soon Thye Lim, Wan Cheng Chow, Alexandre Chan, Tiffany Tang
Abstract
The surveillance protocol is an effective, feasible and cost-saving strategy to manage HBV reactivation among lymphoma patients with resolved HBV infection receiving rituximab.
Related Papers
- → A Novel Estimation of the Impact of Treatment with Entecavir on Long-Term Mortality, Morbidity, and Health Care Costs of Chronic Hepatitis B in China(2013)12 cited
- → Clinical utility of entecavir for chronic hepatitis B in Chinese patients(2013)13 cited
- → Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t) ide-naïve patients with chronic hepatitis B(2015)8 cited
- → Efficacy and safety of long-term therapy with Entecavir (ETV) or Tenofovir (TDF) in patients with HBV-related cirrhosis(2014)1 cited
- → Research progress of entecavir treatment for chronic hepatitis B special patients(2013)